文献速递神经免疫认知障碍与痴呆

血清GFAP动态与多发性硬化进展及治疗反应的关系

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2026-01-01

IMPORTANCE: Capturing individual multiple sclerosis (MS) progression is difficult; few studies have evaluated glial fibrillary acidic protein (GFAP) in large longitudinal cohorts with independent validation.…

要点

  • 血清GFAP升高(z分数>1.0)与后续短期PIRA风险增加相关。
  • 治疗2年内GFAP每年每降低1个z分数与后续PIRA风险降低相关。
  • GFAP可用于PIRA风险分层、治疗监测及临床试验富集筛选。

核心结论

  • 血清GFAP升高与PIRA风险增加相关,而治疗相关GFAP降低与PIRA风险降低相关。
  • 血清GFAP可能作为个性化风险分层、治疗监测及临床试验筛选的生物标志物。

研究设计与样本

  • 前瞻性观察性研究,使用瑞士多发性硬化队列(SMSC,2012年6月启动)和EPIC研究(2004年7月启动)两个大型MS队列。

主要发现

  • 高NfL与接下来一年内的复发风险相关,而高GFAP与长期PIRA风险相关。
  • GFAP z分数>1.0(第84百分位)与后续访视间隔内短期PIRA风险平均增加40%相关(SMSC:HR 1.45,95%CI 1.21-1.75,P<.001;EPIC:HR 1.36,95%CI 1.07-1.71,P=.01)。
  • 在SMSC中,接受芬戈莫德或B细胞清除治疗的前2年内,GFAP z分数每年每降低1个单位分别与后续PIRA风险降低54%(HR 0.46,95%CI 0.26-0.84,P=.01)和67%(HR 0.33,95%CI 0.18-0.61,P<.001)相关。
  • 基于GFAP的队列富集在针对PIRA终点的临床试验中可减少约20%的样本量。

关键数值与推荐

  • PIRA定义:SMSC中为扩展残疾状态量表评分恶化持续6个月以上且无复发;EPIC中为复合终点,额外包括9孔钉柱试验或定时25英尺步行测试恶化>20%。
  • GFAP z分数>1.0对应第84百分位。
  • NfL和GFAP z分数每6或12个月收集并计算。

临床怎么用

  • 血清GFAP可用于MS患者的个性化PIRA风险分层。
  • 系列GFAP监测可辅助评估芬戈莫德或B细胞清除疗法的治疗反应。
  • GFAP可作为临床试验富集筛选工具以减少样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Capturing individual multiple sclerosis (MS) progression is difficult; few studies have evaluated glial fibrillary acidic protein (GFAP) in large longitudinal cohorts with independent validation. OBJECTIVE: To investigate whether serum GFAP levels and treatment-related changes are associated with future progression independent of relapse activity (PIRA). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective observational study using 2 large MS cohorts: the Swiss MS Cohort (SMSC; initiated in June 2012; data extraction September 22, 2025) and the Expression, Proteomics, Imaging, Clinical study (EPIC; initiated in July 2004; data extraction February 21, 2024). The study took place at tertiary MS centers (8 for SMSC and 1 for EPIC). A total of 2329 persons with MS from both cohorts with at least 1 available time point with neurofilament light chain (NfL) and GFAP measurements were included (overall 18 629 measurements). EXPOSURES: Clinical data and NfL and GFAP z scores, collected and calculated every 6 or 12 months. MAIN OUTCOMES AND MEASURES: Risk of future PIRA, defined as Expanded Disability Status Scale score worsening confirmed after 6 or more months without relapses (in SMSC), or a composite additionally including greater than 20% worsening in the 9-hole peg test or timed 25-ft walk test (in EPIC). RESULTS: The SMSC and EPIC cohorts consisted of 1709 (13 375 samples; median [IQR] follow-up, 6.9 [2.5-10.7] years and age, 40.6 [32.1-50.1] years; 1128 [66.0%] female) and 620 (5254 samples; median [IQR] follow-up, 13.1 [9.4-14.0] years and age, 42.0 [35.0-50.0] years; 432 [69.7%] female) persons with MS, respectively. Consistent with prior work, high NfL was associated with relapse risk within the next year, whereas high GFAP was associated with long-term PIRA risk. In addition, elevated GFAP (z score >1.0 [84th percentile]) was associated with an average 40% higher hazard of short-term PIRA in the subsequent visit interval (SMSC: median [IQR] 346 [190-375] days; hazard ratio [HR], 1.45, 95% CI, 1.21-1.75; P < .001; EPIC: 385 [355-518] days; HR, 1.36; 95% CI, 1.07-1.71; P = .01). GFAP-based cohort enrichment in clinical trials targeting PIRA as an end point could reduce sample size by approximately 20%. Further, in SMSC, every yearly GFAP z score unit reduction during the first 2 years receiving fingolimod or B-cell-depleting therapy was associated with a lower risk of subsequent PIRA (54% risk reduction; HR, 0.46; 95% CI, 0.26-0.84; P = .01 and 67% risk reduction; HR, 0.33; 95% CI, 0.18-0.61; P < .001), respectively. CONCLUSIONS AND RELEVANCE: In this cohort study, elevated GFAP was associated with a higher risk of PIRA, while treatment-associated reductions were associated with a lower PIRA risk. Together, these results suggest that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Einsiedler M, Sandgren S, Schaedelin S, et al. Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. JAMA Neurol. 2026. PMID: 42545715. doi:10.1001/jamaneurol.2026.2500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。